NASDAQ:ARVN - Arvinas Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $113.15
Forecasted Upside: 66.11 %
Number of Analysts: 12
Breakdown:
0 Sell Ratings
0 Hold Ratings
12 Buy Ratings
0 Strong Buy Ratings

^$68.12 As of 05/18/2021 02:27 PM ET

▲ +0.88 (1.31%)

1 month | 3 months | 12 months

Get New Arvinas Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$113.15

▲ +66.11% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $113.15, with a high forecast of $150.00 and a low forecast of $45.00. The average price target represents a 66.11% upside from the last price of $68.12.

Buy

The current consensus among 12 polled investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/25/2019

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/23/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/23/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/21/2020

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/19/2020

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/17/2021

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/18/2021

0 strong buy ratings
12 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/18/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/27/2021	Truist Securities	Initiated Coverage	Buy	$150.00	Medium	i
4/21/2021	Northern Trust Capital Markets	Initiated Coverage	Buy		Low	i
4/21/2021	Truist Securities	Initiated Coverage	Buy	$150.00	High	i
4/21/2021	Truist	Initiated Coverage	Buy	$150.00	High	i
3/31/2021	BMO Capital Markets	Initiated Coverage	Outperform	$101.00	High	i
3/30/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$121.00 ➝ $140.00	High	i Rating by A. Young at Cantor Fitzgerald
1/19/2021	Oppenheimer	Boost Price Target		$80.00 ➝ $100.00	Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/5/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$66.00 ➝ $121.00	N/A	i Rating by A. Young at Cantor Fitzgerald
12/21/2020	Piper Sandler	Boost Price Target	Overweight	$58.00 ➝ $97.00	Low	i
12/15/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target		$43.00 ➝ $123.00	High	i
12/15/2020	Smith Barney Citigroup	Boost Price Target		$43.00 ➝ $123.00	High	i
12/15/2020	Roth Capital	Boost Price Target	Buy	$65.00 ➝ $120.00	High	i
12/14/2020	HC Wainwright	Reiterated Rating	Buy	$60.00 ➝ $100.00	High	i
12/14/2020	BMO Capital Markets	Boost Price Target	Outperform	$62.00 ➝ $114.00	High	i
12/14/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/14/2020	The Goldman Sachs Group	Boost Price Target	Buy	$78.00 ➝ $129.00	High	i
12/14/2020	Wedbush	Boost Price Target	Outperform	$62.00 ➝ $93.00	High	i
12/1/2020	Cantor Fitzgerald	Lower Price Target		$75.00 ➝ $66.00	Medium	i Rating by A. Young at Cantor Fitzgerald
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by A. Young at Cantor Fitzgerald
10/8/2020	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/4/2020	Oppenheimer	Initiated Coverage	Hold		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
6/1/2020	Citigroup	Upgrade	Neutral ➝ Buy	$45.00	Medium	i
5/31/2020	Oppenheimer	Initiated Coverage	Hold		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/29/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low	i Rating by Eliana Merle at Cantor Fitzgerald
5/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Medium	i Rating by Eliana Merle at Cantor Fitzgerald
5/11/2020	Oppenheimer	Initiated Coverage	Market Perform		Medium	i
5/4/2020	Roth Capital	Boost Price Target	Buy	$35.00 ➝ $65.00	High	i Rating by Z. Jallah at Roth Capital
4/29/2020	HC Wainwright	Reiterated Rating	Buy	$50.00 ➝ $60.00	Medium	i Rating by A. Fein at HC Wainwright
4/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low	i Rating by Eliana Merle at Cantor Fitzgerald
3/16/2020	Piper Sandler	Reiterated Rating	Buy	$58.00	High	i Rating by Edward Tenthoff at Piper Sandler
1/30/2020	BMO Capital Markets	Reiterated Rating	Outperform	$62.00	High	i
1/24/2020	Wedbush	Boost Price Target	Outperform	$39.00 ➝ $60.00	Medium	i Rating by R. Driscoll at Wedbush
1/6/2020	Piper Jaffray Companies	Boost Price Target	Overweight	$35.00 ➝ $58.00	N/A	i
12/20/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$42.00 ➝ $75.00	Low	i Rating by E. Merle at Cantor Fitzgerald
12/19/2019	HC Wainwright	Initiated Coverage	Buy	$50.00	High	i Rating by A. Fein at HC Wainwright
11/25/2019	Guggenheim	Initiated Coverage	Buy	$50.00	High	i
11/14/2019	Roth Capital	Initiated Coverage	Buy	$35.00	Medium	i Rating by Z. Jallah at Roth Capital
11/13/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$32.00 ➝ $35.00	High	i
10/24/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$23.00 ➝ $38.00	Medium	i
9/24/2019	Wedbush	Initiated Coverage	Outperform	$35.00 ➝ $38.00	Low	i Rating by R. Driscoll at Wedbush
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$34.00	High	i
8/5/2019	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$42.00 ➝ $42.00	Medium	i Rating by E. Merle at Cantor Fitzgerald
6/5/2019	Citigroup	Downgrade	Buy ➝ Neutral	$21.00 ➝ $22.00	High	i
5/8/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$23.00 ➝ $32.00	High	i
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		High	i
10/22/2018	Citigroup	Initiated Coverage	Buy ➝ Buy	$21.00	Low	i
10/22/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.00	High	i
10/22/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$23.00	High	i

(Data available from 5/18/2016 forward)

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $68.12

$67.48

$68.50

50 Day Range

MA: $64.85

$58.19

$69.99

52 Week Range

Now: $68.12

$19.68

$92.77

Volume

10,164 shs

Average Volume

447,086 shs

Market Capitalization

$3.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

The following Wall Street research analysts have issued reports on Arvinas in the last year: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Northern Trust Capital Markets, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, Smith Barney Citigroup, The Goldman Sachs Group, Inc., Truist, Truist Securities, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ARVN.

What is the current price target for Arvinas?

13 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $113.15, suggesting a possible upside of 66.1%. Truist has the highest price target set, predicting ARVN will reach $150.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $45.00 for Arvinas in the next year.
View the latest price targets for ARVN.

What is the current consensus analyst rating for Arvinas?

Arvinas currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARVN will outperform the market and that investors should add to their positions of Arvinas.
View the latest ratings for ARVN.

What other companies compete with Arvinas?

Other companies that are similar to Arvinas include Grifols, Ono Pharmaceutical, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Bausch Health Companies, Jazz Pharmaceuticals, Maravai LifeSciences, United Therapeutics, BridgeBio Pharma, Mirati Therapeutics, Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, Ascendis Pharma A/S, GW Pharmaceuticals and Evotec.

How do I contact Arvinas' investor relations team?

Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected] The official website for Arvinas is www.arvinas.com.